Description: Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Home Page: www.orion.fi
Orionintie 1A
Espoo,
02200
Finland
Phone:
358 10 4261
Officers
| Name | Title |
|---|---|
| Dr. Liisa Hurme Ph.D. | President, CEO & Chairman of Executive Management Board |
| Mr. Rene Lindell M.Sc., Ph.D. | Chief Financial Officer & Member of Group Executive Management Board |
| Mr. Olli Huotari Ll.M. | Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board |
| Mr. Juhani Kankaanpaa | Senior VP of Global Operations & Member of Executive Management Board |
| Mr. Niclas Lindstedt EMBA, M.Sc. | Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board |
| Mr. Hao Pan M.Sc. | Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board |
| Ms. Julia Irene Macharey | Senior Vice President of People & Culture and Member of Management Board |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 29.4118 |
|---|---|
| Trailing PE: | 19.0466 |
| Price-to-Book MRQ: | 6.832 |
| Price-to-Sales TTM: | 4.4158 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3867 |